Ann: Investor Presentation, page-229

"Our study demonstrates that iPSC-derived MSCs can be manufactured using a new cell differentiation and expansion platform that eliminates major issues of supply, scalability and consistency.

Our iPSC-based approach has the potential to overcome the fundamental limitations of conventional, donor-derived MSC production processes, as it facilitates the manufacture of an effectively limitless number of MSCs from a single blood donation. It also avoids the need for excessive culture expansion of differentiated MSCs, by instead harnessing the indefinite replication potential of iPSCs. Performing MSC production under xenogen-, serum- and feeder-free conditions minimizes the potential for contamination with zoonotic agents and further reduces potential sources of variability."

World Class. World First

read all about it: https://www.nature.com/articles/s41591-020-1050-x